ABSTRACT
Introducción: La pandemia derivada de la enfermedad por el nuevo coronavirus 2019 (COVID-19) se ha convertido en una emergencia de salud pública mundial, debido a que puede desarrollar complicaciones que amenazan la vida. Si bien se sabe que el SARS-CoV-2 causa enfermedad pulmonar sustancial, se han observado muchas manifestaciones extrapulmonares, incluyendo el compromiso del sistema gastrointestinal. El megacolon tóxico es una complicación rara pero, potencialmente, mortal que se asocia más con la enfermedad inflamatoria intestinal. Sin embargo, cualquier afección que conduzca a la inflamación del colon puede conducir a una dilatación tóxica. Objetivo: Se presenta el caso de un paciente con un síndrome de dificultad respiratoria aguda secundario a una infección por SARS-COV-2. De manera concomitante presentó un cuadro de dilatación no obstructiva del colon, asociado con toxicidad sistémica. Caso clínico: El desarrollo de megacolon tóxico en un paciente con SARS-COV-2 puede estar justificado debido a que el virus infecta las células huésped a través del receptor de la enzima convertidora de angiotensina 2. Se cumplieron los criterios diagnósticos para megacolon tóxico. Conclusiones: Esta también se encuentra altamente expresada en las células epiteliales intestinales, por lo tanto, se debe considerar su diagnóstico oportuno para una intervención temprana, en aras de reducir la tasa de mortalidad tanto como sea posible(AU)
Introduction: The pandemic derived from the 2019 novel coronavirus disease (COVID-19) has become a global public health emergency, due to the fact that it can develop life-threatening complications. Although SARS-CoV-2 is known to cause substantial lung disease, many extra-pulmonary manifestations have been observed, including involvement of the gastrointestinal system. Toxic mega colon is a rare but life-threatening complication most associated with inflammatory bowel disease. However, any condition that leads to inflammation of the colon can lead to toxic dilation. Objective: To report the case of a patient with ARDS secondary to a SARS-COV-2 infection. Concomitantly, she had non-obstructive dilation of the colon, associated with systemic toxicity. Clinical case report: The development of toxic mega colon in a patient with SARS-COV-2 may be justified because the virus infects host cells through the angiotensin-converting enzyme 2 receptor. The diagnostic criteria for toxic megacolon were met. Conclusions: It is also highly expressed in intestinal epithelial cells, therefore, its timely diagnosis should be considered for early intervention, in order to reduce the mortality rate as much as possible(AU)
Subject(s)
Humans , Gastrointestinal Diseases/epidemiology , Angiotensin-Converting Enzyme 2 , COVID-19/complications , Megacolon, Toxic/epidemiology , EcuadorABSTRACT
Las manifestaciones clínicas del SARS-Cov-2 en niños difieren a la de los adultos, con afección respiratoria, gastrointestinal, dermatológica y/o cardiovascular. La mayoría de los niños son asintomáticos o presentan síntomas leves de la infección por COVID-19. Sin embargo, en los últimos meses se ha identificado un pequeño número de niños que desarrollan respuesta inflamatoria sistémica significativa. A continuación, realizamos una revisión sobre las manifestaciones extrapulmonares del SARS-Cov-2
The clinical manifestations of SARS-Cov-2 in children differ from that of adults, with respiratory, gastrointestinal, dermatological and / or cardiovascular conditions. Most children are asymptomatic or have mild symptoms of COVID-19 infection. However, in recent months, a small number of children have been identified who develop a significant systemic inflammatory response. We review the extrapulmonary manifestations of SARS-Cov-2
Subject(s)
Severe acute respiratory syndrome-related coronavirus/pathogenicity , PediatricsABSTRACT
Background: Dengue is an arthropod borne viral haemorrhagic fever. In India between 2015-2017, 790 deaths have been recorded according to NVBDCP data. Gastrointestinal manifestations are among the most common manifestations in dengue fever, and are most often missed due to lack of awareness. This study aims to find the spectrum of Gastrointestinal manifestations and correlation of GI manifestations with severity of Dengue.Methods: A cross-sectional observational study was conducted on 100 consecutive cases of serologically confirmed Dengue fever. Patients were examined clinically, and laboratory data was assessed till they got discharged. Gastrointestinal manifestations of dengue fever were noted and analyzed.Results: This study included 100 consecutive cases of dengue fever. Mean age of the study population was 32.48+12.40 years of them 77 were males and 23 were female patients. Gastrointestinal manifestations were noted in 96% of the patients. GI manifestations noted were Nausea in 71%, Elevation of transaminases in 59%, vomiting in 54%, pain abdomen in 31%, Ascites in 24% hepatomegaly in 14%, diarrhoea in 13%, Acalculous cholecystitis in 13%, Acute fulminant hepatitis in 6%, Upper GI bleed in 6%, splenomegaly in 5%, and Acute pancreatitis in 4% of patients. Of these, GI manifestations like nausea, vomiting, pain abdomen, GI bleed, ascites, jaundice, elevation of transaminases, acute fulminant hepatitis and acute pancreatitis correlated with severity of Dengue fever . Conclusion: Gastrointestinal manifestations in Dengue fever are much more common than once thought of. In our study it was found in 96 percent of patients making it most common manifestations in dengue fever. Transaminitis and Atypical GI manifestations like acute pancreatitis, acute fulminant hepatitis may indicate severe Dengue. The differential diagnosis of an acute febrile syndrome with abdominal pain or gastrointestinal symptoms in patients living in endemic areas should include Dengue fever.
ABSTRACT
Vasculitis is a group of autoimmune diseases characterized by vascular wall inflammation and necrosis,and often involving multiple organs,including the digestive system,such as gastrointestinal tract,hepatic and biliary system,as well as pancreas. The gastrointestinal manifestations of vasculitis are varied and usually non-specific. Misdiagnosis is frequent especially when gastrointestinal symptoms are the presenting manifestations. In this review,we summarized the gastrointestinal manifestations of vasculitis for facilitating the recognition of these diseases by clinicians.
ABSTRACT
Introducción: la alteración de la microbiota intestinal o Dis- biosis ha sido implicada en los cambios de comportamiento del neurodesarrollo y problemas gastrointestinales en pacientes con trastorno del espectro autista (TEA). Objetivo: evaluar la micro- biota intestinal aeróbica (MGIA) y clasificarla en beneficiosa, transitoria y enteropatógena en niños con TEA en la Unidad de Autismo-Maternidad Concepción Palacios. Pacientes y métodos: desde el 26/02/2015 al 12/05/2015 se estudiaron de forma experimental y prospectiva 39 niños diagnosticados con TEA; en el estudio de la MGIA se utilizaron muestras de heces. Se aplicó una encuesta para recopilar datos epidemiológicos, clínicos y comportamientos del neurodesarrollo. Se propone la clasificación de severidad de la disbiosis en grado I,II,III o ausente para la evaluación de la MGIA. Resultados: Fueron 27 niños (69,23%) y 12 niñas (30,77%), con una edad media de 6,3. Disbiosis 31 (79,5%), Disbiosis ausente 8 (20,5%). Según el grado de disbiosis, 5 (16,13%) Grado I, 7 (22,58%) Grado II, 19 (61,29%) Grado III. Los principales agentes causales de disbiosis fueron Klebsiella spp. 16, Proteus mirabilis 8, Streptococcus sp, 6, Serratia marcensces 5, Candida spp. 4. Dos niños presentaron Campylobacter coli como MGIA patógena. Manifestaciones gastrointestinales: 25,80% dolor abdominal, 16,13% diarrea y 38.7% estreñimiento. Trastornos del neurodesarrollo: 50% aleteos, 34% autoagresión, 61% berrinches, insomnio un 34.3%. Conclusiones: Se hace necesario comparar esta investigación con un grupo de niños sin TEA para confirmar que la presencia de disbiosis como causante de alteración de la MGIA se presenta con más frecuencia en niños con TEA.
Background: altering the intestinal microbiota or Dysbiosis has been implicated in the changes the behavior of neurodevelopmen- tal and gastrointestinal problems in patients with autism spectrum disorder (ASD). Objective: To evaluate aerobic intestinal micro- biota (AMGI) and rank it beneficial, transitory and enteropathogenic in children with ASD, the Autism Unit-Maternidad Concepcion Palacios. Patients and Methods: From 26/02/2015 to 05/12/2015 were studied experimentally and prospectively 39 children diagnosed with ASD; in this study the AMGI stool samples were used. A survey to collect epidemiological, clinical and neurodevelopmental behavior was applied. Severity classification dysbiosis proposed in grade I, II, III or absent for evaluating the AMGI. Results: There were 27 kids (69.23%) and 12 girls (30.77%) with a mean age of 6.3. Dysbiosis 31 (79.5%), Dysbiosis absent eight (20.5%). Depending on the degree of dysbiosis, 5 (16.13%) Grade I, 7 (22.58%) Grade II, 19 (61.29%) Grade III. The main causative agents of dysbiosis were Klebsiella spp. 16, Proteus mirabilis 8, Streptococcus sp. 6, Serratia marcensces 5, Candida spp. 4. Two children presented MGIA pathogenic Campylobacter coli. Gastrointestinal symptoms: 25,80% abdominal pain, 16.13% diarrhea and 38.7% constipation. Neurodevelopmental disorders: 50% flapping, 34% self-harm, 61% tantrums and 34.3% insomnia. Conclusion: It is necessary to compare this research with a group of children without ASD to confirm the presence of dysbiosis to cau- se impaired MGIA occurs most often in children with ASD.
ABSTRACT
Objective To analyze the clinical characteristics of childhood systemic lupus erythematosus (SLE) patients with severe gastrointestinal manifestations,especially cases with acute and severe abdominal pain,so as to improve the recognition of severe and acute gastrointestinal manifestations of SLE during pediatric diagnosis and treatment.Methods Medical records of 119 patients with SLE under the age 16 years old in Peking Union Medical College Hospital from Jan.2010 to Mar.2013 were reviewed and gastrointestinal manifestations were retrospectively analyzed.All patients were diagnosed as SLE according to 1997 American College of Rheumatology (ACR) revised classification criteria.Results Gastrointestinal involvement was recorded in 24 children (20.2％).The median (range) age at the time of initial gastrointestinal manifestations was (13.5 ± 2.0) years (6-15 years).The ratio of female to male was 1.0 ∶ 2.4.And in 4 cases,gastrointestinal manifestations occurred as the initial symptoms.Abdominal pain was the most frequent symptom,present in 13 patients (54.2％),11 cases (45.8％) had nausea and vomiting,4 cases (16.6％) had abdominal distension,and 3 cases (12.5％) had diarrhea.Abnormal liver function was found by lab test in 8 cases,without obvious symptoms or the proofs of any virus infection.Acute and severe abdominal pain was found in 9 cases,of whom 6 patients were diagnosed as intestinal pseudo-obstruction (2 cases with bilateral ureterohydronephrosis),1 case had acute peritonitis with surgery,1 case was diagnosed as protein losing enteropathy and 1 case had acute pancreatitis.Liver impairment also occurred in SLE.All cases got alleviated with the treatment of steroids and immunosuppressive drugs.Significant difference was found in the occurrence of hydroureter and hydronephrosis and albumin concentrations between SLE digestive and non-digestive system involvement children.However,there was no remarkable difference in the erythrocyte sedimentation rate,or the involvement of kidney and blood system and central nervous system between the 2 groups.Conclusions SLE is a common autoimmune disease in children involving multiple systems.The severity of gastrointestinal involvement is underestimated.Gastrointestinal manifestations can be initial symptoms of SLE.Intestinal pseudo-obstruction,protein losing enteropathy,and acute pancreatitis are uncommon but severe gastrointestinal manifestations of SLE patients should be fully recognized.It is vital for pediatric physicians to make early diagnosis and begin timely treatment on SLE with Corticosteroid and cyclophosphamide.
ABSTRACT
We report a 40 year old woman admitted with an acute abdomen. Investigations revealed pancreatitis, bilateral pleural effusion, renal failure, disseminated intravascular coagulation, and scrub IgM ELISA and dengue NS1 positivity. She improved with azithromycin and appropriate pain and fluid management. She also developed central venous catheter-related MRSA sepsis that was managed in the hospital.
ABSTRACT
OBJECTIVE: this study aimed to determine the prevalence and characteristics of gastrointestinal manifestations on initial clinical presentation of acute leukemias (AL) in childhood. MATERIAL AND METHODS: this is a retrospective and descriptive study that assessed medical records of 354 patients with AL from January 1995 to December 2004. RESULTS: acute lymphoid leukemia (ALL) was diagnosed in 273 (77.1%) patients and acute non-lymphocytic leukemia (AML) in 81 (22.9%). There were 210 males (59.4%) and 144 females (40.6%). The most common presenting features were: abdominal pain (19.5% in ALL and 11.8% in AML), nausea and vomiting (14.9 in ALL and 14% in AML), abdominal distention (18.5 in ALL and 8.6% in AML; p 0.024), constipation (5% in ALL and 6.5% in AML), diarrhea (3.6% in ALL and 11.8% in AML; p 0.03%), and gastrointestinal bleeding (7.9% in ALL and 9.7% in AML). Ultrasound scanning was made in 61.1% and hepatomegaly was found on 33.6% and esplenomegaly on 28.5% of the patients with AL. Seventy-seven (21.7%) and 15 (4.2%) patients received nonsteroidal anti-inflammatory drugs and glucocorticoids before the diagnostic of AL. An association is well-defined between abdominal symptoms like nausea, vomiting and pain and use of this therapy but this association did not occurred clearly in this study. CONCLUSIONS: gastrointestinal symptoms are not very well-documented as initial manifestation of leukemia in children and should be considered on the differential diagnosis of gastrointestinal symptoms of unknown etiology in children.
Objetivo: el objetivo del estudio fue determinar la prevalencia y las características de las manifestaciones gastrointestinales en la presentación clínica inicial de las leucemias linfoides agudas (LLA) en la infancia. Materialy métodos: se trata de un estudio descriptivo y retrospectivo que evaluó los registros médicos de 354 pacientescon LLA de enero de 1995 a diciembre de 2004. Resultados: la (LLA) ha sido diagnosticada en 273 (77,1%) pacientes y leucemia mieloide aguda (LMA) en 81 (22,9%). Hubo 210 niños (59,4%) y 144 niñas (40,6%). Los síntomas más comunes de presentaciónhan sido los siguientes: dolor abdominal(19,5% en LLA y 11,8% en el LMA), náuseas y vómitos (14,9 en LLA y 14% en LMA, P 0.024), distensión abdominal (18,5 en LLA y 8,6% en LMA, p 0,024), estreñimiento (5% en LLA y 6,5% en LMA), diarrea (3,6% en LLA y 11,8% en LMA, p 0,03%) y hemorragia gastrointestinal (7,9% en LLA y 9,7% enLMA). La ecografía fue realizada en 61,1% de los pacientes encontrándose hepatomegalia en 33,6% y esplenomegalia en 28,5% con LLA. Setenta y siete (21,7%) y 15 (4,2%) pacientes recibieron los fármacos antiinflamatorios no esteroides y glucocorticoides antes del diagnóstico de LLA. Hay una asociación bien definidaentre síntomas abdominales como náuseas, vómitos y dolor y el uso de esta terapia pero esta asociación no seprodujo claramente en este estudio. Conclusiones: las manifestaciones gastrointestinales no están bien documentadas como manifestaciones iniciales de la leucemia en los niños y debe considerarse en el diagnóstico diferencial de los síntomas gastrointestinales de etiología desconocida en estas edades.